Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,669,436 papers from all fields of science
Search
Sign In
Create Free Account
4-hydroxy-N-desmethyltamoxifen
Known as:
4-hydroxy-N-demethyltamoxifen
, Endoxifen
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Endoxifen:MCnc:Pt:Ser/Plas:Qn
analogs & derivatives
Broader (1)
Tamoxifen
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Analysis of chemotherapy drugs and related compounds in aquatic environment: removal, transformation and risk evaluation in eco-friendly and advanced technologies
L. Climent
2016
Corpus ID: 134539057
In order to evaluate the increasing environmental and human risk of anticancer drugs in the environment, more information needs…
Expand
2016
2016
Abstract P3-07-46: CYPTAM-BRUT 3: Endometrial thickness cannot be used as a marker for tamoxifen metabolization in postmenopausal breast cancer patients
A. Poppe
,
A. Dieudonne
,
+16 authors
P. Neven
2016
Corpus ID: 77314263
Background: Tamoxifen is commonly used for the treatment of all stages of estrogen receptor (ER) positive breast cancer (BC), the…
Expand
2015
2015
Developing analytical approaches to explore the connection between endocrine-active pharmaceuticals in water to effects in fish
T. Jones-Lepp
,
Randi-Laurant Taniguchi-Fu
,
+4 authors
L. Mills
Analytical and Bioanalytical Chemistry
2015
Corpus ID: 5223620
The emphasis of this research project was to develop and optimize a solid-phase extraction method and high-performance liquid…
Expand
2014
2014
In vitro Metabolic Investigational Studies of Herbal-Drug Interactions Leading to Predictive Clinical Outcomes
G. Nance
,
R. Bradford
,
+4 authors
G. Gorman
2014
Corpus ID: 31465469
One main area of our research focuses on the impact of herbal supplements or their individual components on the enzymatic…
Expand
2014
2014
Endoxifen shows promise in breast cancer.
Cancer Discovery
2014
Corpus ID: 36176036
In a phase I trial of endoxifen, a metabolite of tamoxifen, multiple patients with estrogen receptor-positive breast cancer that…
Expand
Review
2013
Review
2013
Hormonal and Non-Hormonal Management of Vasomotor Symptoms: A Narrated Review
O. Tan
,
A. Pinto
,
B. Carr
2013
Corpus ID: 44207917
Background: Vasomotor symptoms (VMS; hot flashes, hot flushes) are the most common complaints of peri- and postmenopausal women…
Expand
2013
2013
Abstract PD3-4: A first-in-human phase I study of the tamoxifen (TAM) metabolite, Z-endoxifen hydrochloride (Z-Endx) in women with aromatase inhibitor (AI) refractory metastatic breast cancer (MBC…
M. Goetz
,
V. Suman
,
+14 authors
M. Ames
2013
Corpus ID: 71954704
Background: AI9s are more effective than TAM in ER+ breast cancer. In AI refractory MBC, the response rate to TAM is 0% (Osborne…
Expand
2010
2010
Personalized dosing of tamoxifen (Tam) based on polymorphisms of CYP2D6 (2D6) and/or low serum endoxyfen levels.
M. Barginear
,
Chunli Yu
,
+7 authors
R. Desnick
2010
Corpus ID: 74309920
e13507 Background: The efficacy of Tam varies widely. Tam is biotransformed to endoxifen and 4-OH-Tam by the cytochrome P450 2D6…
Expand
2009
2009
The Impact of Estrogen Receptor-beta on the Actions of Endoxifen in Breast Cancer Cells.
J. Hawse
,
Xianglin Wu
,
+5 authors
J. Ingle
2009
Corpus ID: 76098633
Review
2008
Review
2008
Clinical Implications of CYP 2 D 6 Genotyping inTamoxifen Treatment for Breast Cancer
V. Dezentjé
,
H. Guchelaar
,
J. Nortier
,
C. V. deVelde
,
H. Gelderblom
2008
Corpus ID: 8461314
In October 2006 the Food and Drug Administration recommended an update in the tamoxifen label to reflect the increased risk of…
Expand